What Vaxdyn does

Vaxdyn S.L. is a clinical-stage Spanish biotechnology company founded in 2011 as a spin-off from the Institute of Biomedicine of Seville, developing multi-valent vaccines to prevent infections caused by antibiotic-resistant bacteria. The company's lead candidate, KapaVax (VXD005), is an inactivated LPS-null (endotoxin-free) whole-cell Acinetobacter baumannii vaccine engineered to display conserved antigens from Pseudomonas aeruginosa and Klebsiella pneumoniae on its cell surface, targeting three of the WHO's most urgent antibiotic-resistant pathogens with a single immunogen. The platform, protected by international patent WO 2015/169809 granted in Europe, the USA, Japan, China, India and Mexico, has been expanded into a broader pipeline including AcinetoVax (monovalent A. baumannii), K-Vax, P-Vax, EcoVax (ExPEC), and AppeVax (veterinary), the last enabling a One-Health approach across human and livestock applications.

Vaxdyn is pre-revenue and not yet commercial, with all vaccine candidates in pre-clinical development and first-in-human proof-of-principle expected in 2025. The company is funded almost entirely by non-dilutive grants — up to US$7.3 million from CARB-X, €1.4 million from Next Generation EU via the Spanish State Research Agency, €397K from EUROSTARS/CDTI — supplemented by a €700K seed round in 2021 from Bionova Capital, Arquimea Group, and the Botín Foundation's Mind the Gap program. Operations are run from a small team of 11-50 employees in Dos Hermanas (Seville), Spain, executing development through an international consortium including Laboratorios Reig Jofre (manufacturing), LEITAT (process development), CSIC, CNM-ISCIII, and the University of Córdoba, with the University of Latvia added as a partner for clinical epidemiology planning.

Target end-markets once commercial include patients with chronic lung disease (COPD, cystic fibrosis, primary ciliary dyskinesia), immunocompromised populations (cancer, transplant, dialysis patients), neonates in low-to-middle-income settings, women with recurrent UTIs, hospital and nursing-home populations, and the porcine livestock industry — addressing a global AMR burden estimated at 700,000 annual deaths and a projected 10 million deaths per year by 2050. Vaxdyn currently positions itself through conference participation (World Vaccine Congress Europe), digital channels, and Spanish media, with no established sales infrastructure or pricing as commercial distribution remains several years away.

Name

Vaxdyn

Legal name

Vaxdyn S.L.

Website

https://vaxdyn.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

11–50 employees

Short description

Vaxdyn is a Spanish clinical-stage biotech developing multi-valent vaccines against WHO priority antibiotic-resistant bacteria, using a proprietary LPS-null whole-cell Acinetobacter baumannii platform led by KapaVax. It is pre-revenue, targeting vulnerable patient populations including COPD, immunocompromised, and neonatal patients.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Vaccines

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)

akta.pro secondary industries

Prophylactic Human Vaccines (routine, pediatric, adult) (HLAAAEAA), Livestock Vaccines (Cattle, Swine, Sheep & Goats) (HLAMAKAB)

Keywords

• Vaccine development
• Antimicrobial resistance
• Multi-valent vaccines
• Whole-cell vaccines
• Biopharmaceutical research

Headquarters

HQ city

Sevilla

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Vaccine Development and Commercialization: Vaxdyn is a clinical-stage biotech company developing vaccines against antibiotic-resistant bacteria. Revenue will be generated through vaccine product sales following regulatory approval. The company has not yet reached commercial stage as its vaccine candidates are in pre-clinical development.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Vaxdyn develops multi-valent inactivated whole-cell vaccines against antibiotic-resistant bacteria using a proprietary LPS-null (endotoxin-free) Acinetobacter baumannii platform that displays conserved outer-membrane antigens from multiple pathogens on the cell surface. The company's lead candidate KapaVax targets three of the WHO's top urgent-threat superbugs (A. baumannii, K. pneumoniae, P. aeruginosa), with pipeline extensions for additional human and veterinary pathogens.

Product overview

Vaxdyn is a vaccine development company offering a platform of inactivated LPS-null (endotoxin-free) whole-cell vaccines based on a proprietary Acinetobacter baumannii strain. The platform has evolved from the monovalent AcinetoVax into a technological infrastructure capable of delivering multi-valent vaccine candidates. The core products include AcinetoVax (monovalent A. baumannii vaccine), KapaVax (trivalent vaccine targeting A. baumannii, K. pneumoniae, and P. aeruginosa), and pipeline candidates K-Vax, P-Vax, EcoVax, and AppeVax, which extend the platform to additional pathogens for human and veterinary applications.

Differentiator

Problem solved

Functional benefit

Products and services

• AcinetoVax (VXD001) Inactivated LPS-null (endotoxin-free) whole-cell Acinetobacter baumannii vaccine for raising active immunity against antibiotic-resistant A. baumannii infections. Foundation candidate of Vaxdyn's platform technology.
• KapaVax (VXD005) Inactivated LPS-null (endotoxin-free) whole-cell Acinetobacter baumannii vaccine displaying at the cell surface multiple conserved antigens from Pseudomonas aeruginosa and Klebsiella pneumoniae. Trivalent vaccine targeting three of the WHO's most urgent antibiotic-resistant bacteria with a single immunogen.
• K-Vax Inactivated LPS-null whole-cell A. baumannii vaccine displaying multiple conserved antigens from Klebsiella pneumoniae on the cell surface, designed to raise immunity against 100% of circulating strains of K. pneumoniae and A. baumannii.
• P-Vax Inactivated LPS-null whole-cell A. baumannii vaccine displaying multiple conserved antigens from Pseudomonas aeruginosa on the cell surface, designed to raise immunity against 100% of circulating strains of P. aeruginosa and A. baumannii.
• EcoVax Inactivated LPS-null whole-cell A. baumannii vaccine displaying multiple conserved antigens from Extraintestinal Pathogenic Escherichia coli (ExPEC) on the cell surface, designed to prevent ExPEC and A. baumannii infections in at-risk community populations.
• AppeVax Inactivated LPS-null whole-cell A. baumannii vaccine displaying multiple conserved antigens from Actinobacillus pleuropneumoniae on the cell surface, designed for prevention of porcine pleuropneumonia in the veterinary industry to reduce antibiotic use in livestock.

Quantifiable outcome

• 50% mortality rate reduction potential for patients with multi-drug resistant infections
• +2 more outcomes

Segments6 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eight partnerships are on record, tiered core, secondary and minor.

• Laboratorios Reig JofrecoreStrategic or Co-development PartnerBarcelona-based international pharmaceutical manufacturer partnering with Vaxdyn in the AMReady consortium for vaccine development and manufacturing. Part of consortium led by Vaxdyn for developing vaccines against AMR pathogens.
• National Center of Microbiology (CNM) of ISCIIIcoreStrategic or Co-development PartnerNational reference laboratory for infectious diseases control in Spain. Key research partner in vaccine development working on immunology and infectious disease aspects of Vaxdyn's vaccine candidates.
• LEITAT Technology CentercoreTechnology or IntegrationTechnology center in Barcelona providing technical expertise for vaccine development and manufacturing process development for Vaxdyn's vaccine candidates.
• CSIC - Institute of Parasitology and Biomedicine López NeyracoreStrategic or Co-development PartnerSpanish National Research Council institute in Granada contributing immunology expertise to Vaxdyn's vaccine development programs including AMReady consortium.
• University of CórdobacoreStrategic or Co-development PartnerFaculty of Veterinary Sciences partnering with Vaxdyn for vaccine development including testing in porcine models for applications in veterinary industry and One-Health approach.
• University of LatviasecondaryStrategic or Co-development PartnerPartner in MultiVAX EUROSTARS project for clinical and commercial vaccination strategy against K. pneumoniae and A. baumannii. Includes Paul Stradins University Hospital in Riga for epidemiology assessment.
• ASEBIOminorOthersSpanish Industry Association for biotech companies; Vaxdyn is a member for industry networking and advocacy.
• BEAM AllianceminorOthersBiotech companies from Europe innovating in Anti-Microbial Resistance research; Vaxdyn is a member for collaboration and advocacy.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• LimmaTech Biologics: Swiss clinical-stage biotech developing vaccines against bacterial pathogens including AMR targets. Most directly comparable peer given similar AMR vaccine focus, European base, and pre-clinical-to-clinical stage profile.
• Affinivax: Vaccine developer using a novel multiple antigen-presenting system (MAPS) platform for bacterial vaccines; acquired by GSK in 2022 for up to $3.3B. Closely comparable vaccine technology platform approach targeting AMR pathogens.
• Integrated Biotherapeutics: US-based biotech developing vaccines and immunotherapies against Staphylococcus aureus and other AMR pathogens. Comparable as a focused AMR vaccine developer with similar pipeline approach.
• Centauri Therapeutics: UK-based AMR-focused biotech developing novel therapeutics and vaccines against drug-resistant infections. Similar European footprint, AMR focus, and pre-clinical/early-clinical profile.

Emerging players

• Intravacc: Dutch vaccine development and contract manufacturing organization developing vaccines against infectious diseases including AMR targets. Comparable as a European vaccine developer with overlapping technology and disease focus.
• Nosopharm: French biotech developing novel antibacterial molecules against AMR pathogens. Adjacent AMR-focused biotech with similar European base and development stage, though addressing treatment rather than prevention.
• HilleVax: Clinical-stage vaccine developer focused on norovirus with VLP-based platform technology. Comparable as a small-cap pre-commercial vaccine platform developer facing similar capital and clinical execution challenges.

Broad incumbents

• Valneva: European specialty vaccine company with approved vaccines (chikungunya, Japanese encephalitis, TBE) and pipeline including AMR-relevant programs. Comparable as a publicly-traded European vaccine company operating at larger scale in same space.
• BioNTech: German mRNA platform leader with publicly disclosed AMR vaccine programs. Potentially the most disruptive competitor as mRNA technology could address Vaxdyn's targets with much larger R&D and manufacturing resources.
• Moderna: US mRNA platform leader exploring bacterial vaccine applications including AMR pathogens. Comparable as a major vaccine platform player whose resources could enable competitive AMR vaccine development at scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/vaxdyn
• LinkedInlinkedin.com/company/vaxdyn

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds5 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vaxdyn